Abbott Laboratories company profile
Company profile
Abbott Laboratories has 122,000 employees and is headquartered in Abbott Park, United States.
With 122,000 employees, the group develops and sells products across four segments: generic pharmaceuticals, anti-infective drugs and influenza vaccines, laboratory and point-of-care diagnostic systems, and nutritional and medical devices. Its diagnostics range includes molecular tests for HIV, SARS-CoV-2, influenza, RSV and strep A, as well as drug and alcohol tests. Its nutritional line covers pediatric and adult formulas and infant formula, while its devices address heart rhythm management, heart failure, vascular and structural heart conditions, neuromodulation and diabetes care through glucose monitoring systems. Sales reach customers in markets worldwide, with the United States accounting for 38.6% of revenue and Germany, China, India, Switzerland, Japan and the United Kingdom each representing between 3.0% and 6.2%.
In the fiscal year ended December 2025, revenue rose 5.7% to USD 44.3 billion and net profit reached USD 6.5 billion. The company is headquartered in Abbott Park, Illinois, and was founded in 1888. It was formerly known as Abbott Alkaloidal Company and took the name Abbott Laboratories in 1915.
Company facts
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Headquarters
- 100 Abbott Park Road, 60064-6400, Abbott Park
- Employees
- 122,000
- Chief executive
- Robert Ford
- Founded
- 1888
- Fiscal year
- January - December
- Listing
- ABT · NYSE
- Indices
- S&P 500
- Currency
- USD
- ISIN
- US0028241000
- Website
- abbott.com
Abbott Laboratories and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Abbott LaboratoriesABT | United States | $187.95B | 122,000 | 15.6% | 40.5 |
| MedtronicMDT | United States | $132.22B | 95,000 | 20.1% | 25.4 |
| StrykerSYK | United States | $117.88B | 56,000 | 24.0% | 33.0 |
| Boston ScientificBSX | United States | $64.27B | 59,000 | 19.6% | 18.7 |
| Edwards LifesciencesEW | United States | $61.61B | 16,000 | 28.8% | 61.6 |
| GE HealthCare TechnologiesGEHC | United States | $37.8B | 54,000 | 13.8% | 17.7 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
